Therapeutic support

BEHAVIORAL3 trials

Sponsors

Imperial College London, University Hospital, Basel, Switzerland, The University of Texas Health Science Center, Houston

Conditions

Bipolar II DisorderDepression, BipolarFibromyalgiaPromoting Dignity, Meaningfulness and Mindfulness in Acute Palliative CareSuicidality

Phase 2

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

RecruitingNCT06706232

The University of Texas Health Science Center, HoustonBipolar II Disorder, Depression, Bipolar, Suicidality

Start: 2025-07-07End: 2027-08-01Target: 10Updated: 2026-08-12

Unknown Phase

Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action

Active, not recruitingNCT05548075

Imperial College LondonFibromyalgia

Start: 2022-08-15End: 2024-07-30Target: 20Updated: 2024-01-19

Therapeutic Support to Strengthen Dignity, Mental Well-being and Quality of Life in Acute Palliative Care Patients.

Not yet recruitingNCT06549075

University Hospital, Basel, SwitzerlandPromoting Dignity, Meaningfulness and Mindfulness in Acute Palliative Care

Start: 2024-09-10End: 2025-04-30Target: 40Updated: 2024-08-12

Related Papers

Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study.

2026-07-13

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial

Frontiers in Pain Research2025-03-1811 citations